Formycon 
Welcome,         Profile    Billing    Logout  
 3 Products   0 Diseases  3 Products   2 Trials   19 News 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cimerli (ranibizumab-eqrn) / Amneal, Formycon, Coherus Oncology, Teva, Bio Usawa, Bioeq AG
NCT06708624: Ocular Safety and Usability Study for FYB201 PFS

Completed
4
31
US
FYB201 0.5 mg (0.05 mL of 10 mg/mL), ranibizumab-eqrn
Formycon AG
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema
08/24
08/24
Otulfi (ustekinumab-aauz) / Formycon, Fresenius Kabi
VESPUCCI, NCT04595409 / 2019-004364-21: A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis

Completed
3
392
Europe, RoW
FYB202 (Proposed ustekinumab biosimilar), Stelara® (Ustekinumab)
Bioeq GmbH, bioeq GmbH
Plaque Psoriasis
06/21
03/22
2019-004364-21: A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara in Patients with Moderate-to-Severe Plaque Psoriasis

Not yet recruiting
3
392
Europe
ustekinumab, Stelara, FYB202, Solution for injection in pre-filled syringe, Stelara
bioeq GmbH, bioeq GmbH
Moderate-to-Severe Plaque Psoriasis, Moderate-to-Severe Plaque Psoriasis, Diseases [C] - Immune System Diseases [C20]
 
 
Ahzantive (aflibercept-mrbb) / Amneal, Formycon, Coherus Oncology, Klinge Pharma, Teva, MS Pharma, Alvogen, Valorum Biologics
FYB203-04-01, NCT06708637: Ocular Safety and Usability Study for FYB203 PFS

Completed
4
30
US
FYB203 2 mg (0.05 mL of 40 mg/mL), aflibercept-mrbb
Formycon AG
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema, Diabetic Macular Edema, Diabetic Retinopathy
10/24
10/24
MAGELLAN-AMD, NCT04522167 / 2019-003923-39: Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration

Completed
3
434
Europe, Japan, RoW
FYB203 (Proposed aflibercept biosimilar), Eylea® (Aflibercept)
Bioeq GmbH
Neovascular Age-related Macular Degeneration
06/22
05/23
FYB206 (pembrolizumab biosimilar) / Formycon
Lotus, NCT06643117: Similar Efficacy, Safety, and Immunogenicity of FYB206 in Comparison to Keytruda as add-on to Chemotherapy in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC)

Terminated
3
25
RoW
FYB206, Keytruda
Formycon AG
Non Small Cell Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer
05/25
05/25
Dahlia, NCT06551064: Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients

Recruiting
1
94
Europe, RoW
FYB206, Keytruda
Formycon AG
Melanoma, Stage II, Melanoma Stage III
06/26
06/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cimerli (ranibizumab-eqrn) / Amneal, Formycon, Coherus Oncology, Teva, Bio Usawa, Bioeq AG
NCT06708624: Ocular Safety and Usability Study for FYB201 PFS

Completed
4
31
US
FYB201 0.5 mg (0.05 mL of 10 mg/mL), ranibizumab-eqrn
Formycon AG
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema
08/24
08/24
Otulfi (ustekinumab-aauz) / Formycon, Fresenius Kabi
VESPUCCI, NCT04595409 / 2019-004364-21: A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis

Completed
3
392
Europe, RoW
FYB202 (Proposed ustekinumab biosimilar), Stelara® (Ustekinumab)
Bioeq GmbH, bioeq GmbH
Plaque Psoriasis
06/21
03/22
2019-004364-21: A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara in Patients with Moderate-to-Severe Plaque Psoriasis

Not yet recruiting
3
392
Europe
ustekinumab, Stelara, FYB202, Solution for injection in pre-filled syringe, Stelara
bioeq GmbH, bioeq GmbH
Moderate-to-Severe Plaque Psoriasis, Moderate-to-Severe Plaque Psoriasis, Diseases [C] - Immune System Diseases [C20]
 
 
Ahzantive (aflibercept-mrbb) / Amneal, Formycon, Coherus Oncology, Klinge Pharma, Teva, MS Pharma, Alvogen, Valorum Biologics
FYB203-04-01, NCT06708637: Ocular Safety and Usability Study for FYB203 PFS

Completed
4
30
US
FYB203 2 mg (0.05 mL of 40 mg/mL), aflibercept-mrbb
Formycon AG
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema, Diabetic Macular Edema, Diabetic Retinopathy
10/24
10/24
MAGELLAN-AMD, NCT04522167 / 2019-003923-39: Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration

Completed
3
434
Europe, Japan, RoW
FYB203 (Proposed aflibercept biosimilar), Eylea® (Aflibercept)
Bioeq GmbH
Neovascular Age-related Macular Degeneration
06/22
05/23
FYB206 (pembrolizumab biosimilar) / Formycon
Lotus, NCT06643117: Similar Efficacy, Safety, and Immunogenicity of FYB206 in Comparison to Keytruda as add-on to Chemotherapy in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC)

Terminated
3
25
RoW
FYB206, Keytruda
Formycon AG
Non Small Cell Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer
05/25
05/25
Dahlia, NCT06551064: Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients

Recruiting
1
94
Europe, RoW
FYB206, Keytruda
Formycon AG
Melanoma, Stage II, Melanoma Stage III
06/26
06/26

Download Options